Healthcare
Gossamer Bio, Inc.(GOSS)
Live Price
Offline$0.168
-6.15% today
1Y Change
-87.65%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $80.00M
- Revenue Growth
- -57.7%
- EPS Growth
- -200.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Gossamer Bio, Inc. (GOSS) is a Healthcare stock with a market cap of $80.00M and listed on NASDAQ. The stock last traded around $0.17 and down 87.6% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -57.7%, EPS growth of -200.0%, a dividend yield of 0.0%. What stands out right now is revenue -57.7%, EPS -200.0%, free cash flow -4840.7% with operating margin -352.2% and ROIC -155.5%. Valuation is more restrained than many high-expectation growth names at price/sales 1.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GOSS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-57.7% vs +7.6% peer median
Operating Margin
Below sector median
-352.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -57.7% and EPS is at -200.0%, with operating margin around -352.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | +4.5% | +14.9% | โ |
2026 Mar 17, 2026 | -5.0% | -8.1% | -26.9% | -4.4% |
2025 Nov 5, 2025 | -10.5% | -2.5% | +13.9% | +40.1% |
Benchmark Edge
GOSS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GOSS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GOSS Max Drawdown
-95.88%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GOSS and SPY.
Company Overview
Gossamer Bio, Inc.
NASDAQ Global Select
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
- Leadership
- Faheem Hasnain
- IPO Date
- Feb 8, 2019
- Employees
- 144
- Street Address
- 3013 Science Park Road
- Mailing
- San Diego, CA, 92121
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 684 1300
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.7
- Price/Book
- โ
Growth
- Revenue
- -57.7%
- EPS
- -200.0%
- Free Cash Flow
- -4840.7%
Profitability
- Gross Margin
- 99.5%
- Operating Margin
- -352.2%
- Net Margin
- -351.5%
- ROE
- 264.7%
- ROIC
- -155.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.64
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.